Earning Preview: Medtronic PLC revenue this quarter is expected to increase by 6.95%, and institutional views are bullish

Earnings Agent11-17 08:43

Abstract

Medtronic PLC will release its fiscal second-quarter 2027 results on November 24, 2026 Pre-MKt, with current-quarter consensus pointing to revenue of 9.48 billion US dollars, adjusted EPS of 1.33 US dollars, and EBIT of 2.18 billion US dollars, alongside continued momentum in electrophysiology and portfolio expansion.

Market Forecast

Consensus for the current quarter calls for revenue of 9.48 billion US dollars, up 6.95% year over year, adjusted EPS of 1.33 US dollars, up 1.28% year over year, and EBIT of 2.18 billion US dollars, up 1.19% year over year; no formal guidance was provided for gross profit margin or net margin in the current-quarter outlook. Core portfolio momentum remains centered on cardiovascular therapies and strengthening contributions from newer growth platforms, while diabetes separation and targeted M&A reinforce the focus on scalable growth; the company’s most promising platform is electrophysiology, where revenue in the last reported quarter reached 2.22 billion US dollars with 29.10% year-over-year organic growth.

Last Quarter Review

In the fiscal first quarter of 2027 (ended July 31, 2026), Medtronic PLC delivered revenue of 9.76 billion US dollars, a gross profit margin of 65.07%, GAAP net profit attributable to the parent company of 1.47 billion US dollars, a net profit margin of 15.07%, and adjusted EPS of 1.45 US dollars, up 15.08% year over year. A key highlight was disciplined execution that lifted revenue 14.25% year over year and adjusted EPS above guidance, with quarter-on-quarter net profit growth of 18.17%. Main business highlights included cardiovascular portfolio revenue of 3.93 billion US dollars growing 18.90% organic year over year, neuroscience revenue of 2.68 billion US dollars up 9.30% organic, medical surgical revenue of 2.28 billion US dollars up 10.20% organic, and diabetes revenue of 843.00 million US dollars up 14.90% organic.

Current Quarter Outlook

Cardiovascular Portfolio

Cardiovascular remains the primary earnings engine this quarter, supported by consistent demand in cardiac rhythm management, sustained uptake in electrophysiology, and healthy trends in vascular and cardiac surgery franchises. The company’s last reported quarter showed cardiovascular revenue of 3.93 billion US dollars, up 18.90% year over year on an organic basis, reinforcing the durability of demand entering the current period. With recent regulatory milestones in cardiac ablation-related software (Affera Prism-2) and functionality enhancements for pulsed-field ablation workflows, product positioning supports continued procedure growth and premium mix. Given the forecast for total company revenue to rise 6.95% year over year, cardiovascular’s scale and growth profile indicate it should remain the chief contributor to top-line expansion, with margin mix helped by higher-value therapies.

Electrophysiology and Cardiac Ablation Solutions

Electrophysiology has emerged as the most promising growth platform, reporting 2.22 billion US dollars in revenue in the prior quarter with 29.10% organic growth, and Cardiac Ablation Solutions expanding 88% year over year. The momentum reflects rapid adoption of mapping and ablation technologies, aided by software advances that simplify workflows and provide more actionable intra-procedural data. Broader availability and expanded indications in select regions further enlarge the addressable opportunity, while the company’s sustained investments in innovation are aligning with favorable procedure demand trends. In the current quarter, this franchise is well-placed to outgrow corporate averages again, helping offset cost headwinds and supporting EBIT stability as the business scales.

Portfolio Optimization, Capital Deployment, and Margin Levers

Portfolio actions and capital allocation choices are meaningful stock drivers this quarter. Medtronic completed an oversubscribed exchange of its remaining MiniMed shares, removing an overhang and sharpening focus on core growth platforms, which should aid earnings quality and simplify investor narratives. Recent bolt-on deals, including the completed acquisition of Scientia Vascular and the announced plan to acquire Contego Medical, broaden capabilities in neurovascular and carotid technologies; management expects minimal near-term earnings dilution, positioning these assets to contribute accretively after integration. On margins, while the company has not provided a current-quarter gross or net margin outlook, mix tailwinds from higher-growth franchises and disciplined operating execution are key levers, and consensus EBIT growth of 1.19% year over year indicates expectations for resilient profitability despite investments and integration costs.

Diabetes and Medical Surgical Execution

Diabetes and Medical Surgical sustained solid double-digit organic growth in the last reported quarter, with diabetes revenue of 843.00 million US dollars up 14.90% and medical surgical revenue of 2.28 billion US dollars up 10.20% organically. These businesses provide breadth to the company’s growth base and incremental operating leverage as supply and fulfillment normalize. The strategic separation of diabetes-related equity holdings and associated capital structure steps aim to streamline operations and capital allocation priorities. As the company integrates acquisitions and continues selective product launches in medical surgical and patient monitoring, these segments should provide steady contributions, even if the narrative remains centered on cardiovascular and electrophysiology.

Regulatory Milestones and Product Cycle Timing

Recent clearances and CE Marks for electrophysiology mapping and ablation software suggest continued cadence in product enhancements that can raise utilization, shorten procedure times, and improve physician confidence. The pace of regulatory achievements aligns with the internal innovation plan and supports a multi-quarter product cycle that may sustain above-market growth in targeted franchises. Timing of launches, regional rollouts, and training capacity are practical considerations for near-term revenue conversion; however, the breadth of the portfolio has historically helped mitigate timing variability in any single platform.

Revenue, EPS, and EBIT Anchors for This Quarter

Against this operational backdrop, the current-quarter consensus anchors are revenue of 9.48 billion US dollars, up 6.95% year over year, adjusted EPS of 1.33 US dollars, up 1.28% year over year, and EBIT of 2.18 billion US dollars, up 1.19% year over year. These metrics imply expectations for steady growth with incremental margin expansion primarily through mix and execution rather than outsized price or cost leverage. Absence of a formal margin outlook suggests the focus will be on evidence of operating discipline, cash conversion, and confirmation that recent portfolio moves enhance long-term growth and profitability.

Key Watch Items for the Print

Investors will look for signs that electrophysiology’s momentum is translating into sustained order flow and that procedure pipelines remain healthy across major geographies. Commentary on integration progress for recent acquisitions and the timeline for Contego Medical’s contribution will be important to sizing incremental growth. Management’s discussion of inventory, supply dynamics, and any color around operating expense trajectory will frame how much of the current revenue growth can drop to the bottom line in the back half of fiscal 2027.

Analyst Opinions

Analyst opinions skew bullish. Recent updates highlight multiple Buy ratings, including RBC Capital (Kendall Au, price target 118 US dollars), TD Cowen (Josh Jennings, price target 110–119 US dollars), Wells Fargo (Larry Biegelsen, price target 102 US dollars), and Evercore ISI (Vijay Kumar, price target 106 US dollars), while J.P. Morgan and Piper Sandler reiterated Hold views. The balance of commentary emphasizes consistent upside in cardiovascular and electrophysiology franchises, progress in product and software pipelines, and a cleaner capital structure following the exchange of remaining MiniMed shares. Several notes also point to supportive consensus signals: a rise in fiscal 2027 guidance at the last print, steady EBIT delivery, and incremental contributions from targeted M&A. The bullish camp expects the current quarter to validate continued momentum, citing the 6.95% year-over-year revenue growth outlook, 1.28% adjusted EPS growth, and the potential for product-cycle-driven outperformance in electrophysiology and ablation. In aggregate, the Buy cohort outnumbers neutral views, and their case rests on durable core growth, improving operating discipline, and the prospect that recent accretive moves and regulatory milestones will sustain a favorable earnings trajectory into the second half of fiscal 2027.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment